Recent progress in tight junction modulation for improving bioavailability

Bibliography

• Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993;123(6 Pt 2):1777-88
   PubMed Web of Science ®Google Scholar
• Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998;141(7):1539-50
   PubMed Web of Science ®Google Scholar
• Lal-Nag M, Morin PJ. The claudins. Genome Biol 2009;10(8):235
   PubMed Web of Science ®Google Scholar
• Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 1986;103(3):755-66
   PubMed Web of Science ®Google Scholar
• Gumbiner B, Lowenkopf T, Apatira D. Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1. Proc Natl Acad Sci USA 1991;88(8):3460-4
   PubMed Web of Science ®Google Scholar
• Balda MS, Gonzalez-Mariscal L, Matter K, et al. Assembly of the tight junction: the role of diacylglycerol. J Cell Biol 1993;123(2):293-302
   PubMed Web of Science ®Google Scholar
• Ebnet K, Suzuki A, Ohno S, Vestweber D. Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci 2004;117(Pt 1):19-29
   PubMed Web of Science ®Google Scholar
• van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006;68:403-29
   PubMed Web of Science ®Google Scholar
• Claude P, Goodenough DA. Fracture faces of zonulae occludentes from “tight” and “leaky” epithelia. J Cell Biol 1973;58(2):390-400
   PubMed Web of Science ®Google Scholar
• Farkas AE, Capaldo CT, Nusrat A. Regulation of epithelial proliferation by tight junction proteins. Ann NY Acad Sci 2012;1258:115-24
   PubMed Web of Science ®Google Scholar
• Kurasawa M, Maeda T, Oba A, et al. Tight junction regulates epidermal calcium ion gradient and differentiation. Biochem Biophys Res Commun 2011;406(4):506-11
   PubMed Web of Science ®Google Scholar
• Kirschner N, Brandner JM. Barriers and more: functions of tight junction proteins in the skin. Ann NY Acad Sci 2012;1257:158-66
   PubMed Web of Science ®Google Scholar
• Matter K, Aijaz S, Tsapara A, Balda MS. Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. Curr Opin Cell Biol 2005;17(5):453-8
   PubMed Web of Science ®Google Scholar
• Mullin JM, Agostino N, Rendon-Huerta E, Thornton JJ. Keynote review: epithelial and endothelial barriers in human disease. Drug Discov Today 2005;10(6):395-408
   PubMed Web of Science ®Google Scholar
• Cereijido M, Contreras RG, Flores-Benítez D, et al. New diseases derived or associated with the tight junction. Arch Med Res 2007;38(5):465-78
   PubMed Web of Science ®Google Scholar
• Li AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 2001;6(7):357-66
   PubMed Web of Science ®Google Scholar
• Watson CJ, Rowland M, Warhurst G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol 2001;281(2):C388-97
   PubMed Web of Science ®Google Scholar
• Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980;23(6):682-4
   PubMed Web of Science ®Google Scholar
• Van Itallie CM, Holmes J, Bridges A, et al. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci 2008;121(Pt 3):298-305
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11(4):265-83
   PubMed Web of Science ®Google Scholar
• Karnaky KJ Jr. Electrophysiological assessment of epithelia. In: Stevenson BR, Waren JG, Paul DL, editors, Cell-cell interactions: a practical approach. IRL Press, Oxford; 1992. p. 257-74
   Google Scholar
• Günzel D, Zakrzewski SS, Schmid T, et al. From TER to trans- and paracellular resistance: lessons from impedance spectroscopy. Ann NY Acad Sci 2012;1257:142-51
   PubMed Web of Science ®Google Scholar
• Krug SM, Fromm M, Günzel D. Two-path impedance spectroscopy for measuring paracellular and transcellular epithelial resistance. Biophys J 2009;97(8):2202-11
   PubMed Web of Science ®Google Scholar
• Ballal NV, Kundabala M, Bhat S, et al. A comparative in vitro evaluation of cytotoxic effects of EDTA and maleic acid: root canal irrigants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108(4):633-8
   PubMed Web of Science ®Google Scholar
• Ranaldi G, Marigliano I, Vespignani I, et al. The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line(1). J Nutr Biochem 2002;13(3):157-67
   PubMed Web of Science ®Google Scholar
• Morgan DM, Clover J, Pearson JD. Effects of synthetic polycations on leucine incorporation, lactate dehydrogenase release, and morphology of human umbilical vein endothelial cells. J Cell Sci 1988;91(Pt 2):231-8
   PubMedGoogle Scholar
• Scott Swenson E, Curatolo WJ. C) Means to enhance penetration. Adv Drug Deliv Rev 1992;8(1):39-92
   Web of Science ®Google Scholar
• Kondoh M, Takahashi A, Yagi K. Spiral progression in the development of absorption enhancers based on the biology of tight junctions. Adv Drug Deliv Rev 2012;64(6):515-22
   PubMed Web of Science ®Google Scholar
• Turner JR, Angle JM, Black ED, et al. PKC-dependent regulation of transepithelial resistance: roles of MLC and MLC kinase. Am J Physiol 1999;277(3 Pt 1):C554-62
   Google Scholar
• Rodgers LS, Fanning AS. Regulation of epithelial permeability by the actin cytoskeleton. Cytoskeleton (Hoboken) 2011;68(12):653-60
   PubMed Web of Science ®Google Scholar
• Peti W, Nairn AC, Page R. Structural basis for protein phosphatase 1 regulation and specificity. FEBS J 2012;280(2):596-611
   PubMed Web of Science ®Google Scholar
• Carman AJ, Mills JH, Krenz A, et al. Adenosine receptor signaling modulates permeability of the blood-brain barrier. J Neurosci 2011;31(37):13272-80
   PubMed Web of Science ®Google Scholar
• Umapathy NS, Fan Z, Zemskov EA, et al. Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement. Vascul Pharmacol 2010;52(5-6):199-206
   PubMed Web of Science ®Google Scholar
• Terry S, Nie M, Matter K, Balda MS. Rho signaling and tight junction functions. Physiology (Bethesda) 2010;25(1):16-26
   PubMed Web of Science ®Google Scholar
• Sharp CD, Hines I, Houghton J, et al. Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol Heart Circ Physiol 2003;285(6):H2592-8
   PubMed Web of Science ®Google Scholar
• Guo Y, Ramachandran C, Satpathy M, Srinivas SP. Histamine-induced myosin light chain phosphorylation breaks down the barrier integrity of cultured corneal epithelial cells. Pharm Res 2007;24(10):1824-33
   PubMed Web of Science ®Google Scholar
• Srinivas SP, Satpathy M, Guo Y, Anandan V. Histamine-induced phosphorylation of the regulatory light chain of myosin II disrupts the barrier integrity of corneal endothelial cells. Invest Ophthalmol Vis Sci 2006;47(9):4011-18
   PubMed Web of Science ®Google Scholar
• Kuhlmann CRW, Gerigk M, Bender B, et al. Fluvastatin prevents glutamate-induced blood-brain-barrier disruption in vitro. Life Sci 2008;82(25-26):1281-7
   PubMed Web of Science ®Google Scholar
• Balda MS, González-Mariscal L, Contreras RG, et al. Assembly and sealing of tight junctions: possible participation of G-proteins, phospholipase C, protein kinase C and calmodulin. J Membr Biol 1991;122(3):193-202
   PubMed Web of Science ®Google Scholar
• Denker BM, Saha C, Khawaja S, Nigam SK. Involvement of a heterotrimeric G protein alpha subunit in tight junction biogenesis. J Biol Chem 1996;271(42):25750-3
   PubMed Web of Science ®Google Scholar
• Deli MA, Abrahám CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005;25(1):59-127
   PubMed Web of Science ®Google Scholar
• Broccatelli F, Cruciani G, Benet LZ, Oprea TI. BDDCS class prediction for new molecular entities. Mol Pharm 2012;9(3):570-80
   PubMed Web of Science ®Google Scholar
• Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm 2012;2012:195727
   PubMedGoogle Scholar
• Buchert M, Turksen K, Hollande F. Methods to examine tight junction physiology in cancer stem cells: TEER, paracellular permeability, and dilution potential measurements. Stem Cell Rev 2012;8(3):1030-4
   PubMed Web of Science ®Google Scholar
• Sanders SE, Madara JL, McGuirk DK, et al. Assessment of inflammatory events in epithelial permeability: a rapid screening method using fluorescein dextrans. Epithelial Cell Biol 1995;4(1):25-34
   PubMedGoogle Scholar
• Veshnyakova A, Protze J, Rossa J, et al. On the interaction of Clostridium perfringens enterotoxin with claudins. Toxins (Basel) 2010;2(6):1336-56
   PubMedGoogle Scholar
• Veshnyakova A, Piontek J, Protze J, et al. Mechanism of Clostridium perfringens enterotoxin interaction with claudin-3/-4 protein suggests structural modifications of the toxin to target specific claudins. J Biol Chem 2012;287(3):1698-708
   PubMed Web of Science ®Google Scholar
• Tscheik C, Blasig IE, Winkler L. Trends in drug delivery through tissue barriers containing tight junctions. Tissuebarriers 2013;1(2):e24565
   Google Scholar
• Del Vecchio G, Tscheik C, Tenz K, et al. Sodium caprate transiently opens claudin-5-containing barriers at tight junctions of epithelial and endothelial cells. Mol Pharm 2012;9(9):2523-33
   PubMedGoogle Scholar
• Zwanziger D, Hackel D, Staat C, et al. A peptidomimetic tight junction modulator to improve regional analgesia. Mol Pharm 2012;9(6):1785-94
   PubMedGoogle Scholar
• Wysolmerski RB, Lagunoff D. Regulation of permeabilized endothelial cell retraction by myosin phosphorylation. Am J Physiol 1991;261(1 Pt 1):C32-40
   Google Scholar
• Tinsley JH, de Lanerolle P, Wilson E, et al. Myosin light chain kinase transference induces myosin light chain activation and endothelial hyperpermeability. Am J Physiol Cell Physiol 2000;279(4):C1285-9
   Google Scholar
• Straub JA, Akiyama A, Parmar P. In vitro plasma metabolism of RMP-7. Pharm Res 1994;11(11):1673-6
   PubMed Web of Science ®Google Scholar
• Shepro D, Morel NM. Pericyte physiology. FASEB J 1993;7:1031-8
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001;1(1):59-64
   PubMedGoogle Scholar
• Dean RL, Emerich DF, Hasler BP, Bartus RT. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro-oncol 1999;1(4):268-74
   PubMedGoogle Scholar
• Mackic JB, Stins M, Jovanovic S, et al. Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharm Res 1999;16(9):1360-5
   PubMed Web of Science ®Google Scholar
• Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996;39(1):125-33; discussion 133-4
   PubMed Web of Science ®Google Scholar
• Elliott PJ, Hayward NJ, Dean RL, et al. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 1996;56(17):3998-4005
   PubMed Web of Science ®Google Scholar
• Bartus RT, Elliott P, Hayward N, et al. Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology 1996;33(1-3):270-8
   PubMedGoogle Scholar
• Ford J, Osborn C, Barton T, Bleehen NM. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 1998;34(11):1807-11
   PubMed Web of Science ®Google Scholar
• Warren KE, Patel MC, Aikin AA, et al. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol 2001;48(4):275-82
   PubMed Web of Science ®Google Scholar
• Packer RJ, Krailo M, Mehta M, et al. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer 2005;104(9):1968-74
   PubMed Web of Science ®Google Scholar
• Gregor A, Lind M, Newman H, et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group. J Neurooncol 1999;44(2):137-45
   PubMed Web of Science ®Google Scholar
• Prados MD, Schold SC JR SC, Fine HA, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncol 2003;5(2):96-103
   PubMed Web of Science ®Google Scholar
• Emerich DF, Snodgrass P, Dean R, et al. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer 1999;80(7):964-70
   PubMed Web of Science ®Google Scholar
• Warren K, Jakacki R, Widemann B, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 2006;58(3):343-7
   PubMed Web of Science ®Google Scholar
• Di Pierro M, Lu R, Uzzau S, et al. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem 2001;276(22):19160-5
   PubMed Web of Science ®Google Scholar
• Song K, Fasano A, Eddington ND. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. Int J Pharm 2008;351(1-2):8-14
   PubMedGoogle Scholar
• Fasano A, Baudry B, Pumplin DW, et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 1991;88(12):5242-6
   PubMed Web of Science ®Google Scholar
• Fasano A, Fiorentini C, Donelli G, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995;96(2):710-20
   PubMed Web of Science ®Google Scholar
• Fasano A, Uzzau S, Fiore C, Margaretten K. The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 1997;112(3):839-46
   PubMed Web of Science ®Google Scholar
• Fasano A, et al. P0517 Zot/Zonulin-mediated regulation of intestinal tight junctions involves the proteinase-activated receptor 2 (Par-2). J Pediatr Gastroenterol Nutr 2004;39:253-4
   PubMedGoogle Scholar
• Cox DS, Gao H, Raje S, et al. Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur J Pharm Biopharm 2001;52(2):145-50
   PubMed Web of Science ®Google Scholar
• Cox DS, Raje S, Gao H, et al. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm Res 2002;19(11):1680-8
   PubMed Web of Science ®Google Scholar
• Karyekar CS, Fasano A, Raje S, et al. Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J Pharm Sci 2003;92(2):414-23
   PubMed Web of Science ®Google Scholar
• Fasano A, Uzzau S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997;99(6):1158-64
   PubMed Web of Science ®Google Scholar
• Salama NN, Fasano A, Lu R, Eddington ND. Effect of the biologically active fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral absorption of mannitol. Int J Pharm 2003;251(1-2):113-21
   PubMedGoogle Scholar
• Salama NN, Fasano A, Thakar M, Eddington ND. The effect of ΔG on the transport and oral absorption of macromolecules. J Pharm Sci 2004;93(5):1310-19
   PubMed Web of Science ®Google Scholar
• Salama NN, Fasano A, Thakar M, Eddington ND. The impact of ΔG on the oral bioavailability of low bioavailable therapeutic agents. J Pharmacol Exp Ther 2005;312(1):199-205
   PubMed Web of Science ®Google Scholar
• Menon D, Karyekar CS, Fasano A, et al. Enhancement of brain distribution of anticancer agents using ΔG, the 12 kDa active fragment of ZOT. Int J Pharm 2005;306(1–2):122-31
   PubMedGoogle Scholar
• Goldblum SE, Rai U, Tripathi A, et al. The active Zot domain (aa 288–293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J 2011;25(1):144-58
   PubMed Web of Science ®Google Scholar
• Li M, Oliver E, Kitchens KM, et al. Structure–activity relationship studies of permeability modulating peptide AT-1002. Bioorg Med Chem Lett 2008;18(16):4584-6
   PubMed Web of Science ®Google Scholar
• Song K, Eddington N. The influence of stabilizer and bioadhesive polymer on the permeation-enhancing effect of AT1002 in the nasal delivery of a paracellular marker. Arch Pharm Res 2012;35(2):359-66
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, Pandey N, Tamiz AP, et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm 2009;365(1–2):121-30
   PubMed Web of Science ®Google Scholar
• Song K, Eddington ND. The influence of AT1002 on the nasal absorption of molecular weight markers and therapeutic agents when co-administered with bioadhesive polymers and an AT1002 antagonist, AT1001. J Pharm Pharmacol 2012;64(1):30-9
   PubMed Web of Science ®Google Scholar
• Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007;26(5):757-66
   PubMed Web of Science ®Google Scholar
• Hollenberg MD. Proteinase-mediated signaling: Proteinase-activated receptors (PARs) and much more. Life Sci 2003;74(2–3):237-46
   PubMed Web of Science ®Google Scholar
• Hollenberg MD, Oikonomopoulou K, Hansen KK, et al. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem 2008;389(6):643-51
   PubMed Web of Science ®Google Scholar
• Hollenberg MD. Physiology and pathophysiology of proteinase-activated receptors (PARs): proteinases as hormone-like signal messengers: PARs and more. J Pharm Sci 2005;97(1):8-13
   Web of Science ®Google Scholar
• Barry GD, Suen JY, Le GT, et al. Novel agonists and antagonists for human protease activated receptor 2. J Med Chem 2010;53(20):7428-40
   PubMed Web of Science ®Google Scholar
• Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000;97(10):5255-60
   PubMed Web of Science ®Google Scholar
• Kawabata A, Oono Y, Yonezawa D, et al. 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. Br J Pharmacol 2005;144(2):212-19
   PubMed Web of Science ®Google Scholar
• Cenac N, Chin AC, Garcia-Villar R, et al. PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways. J Physiol 2004;558(3):913-25
   PubMed Web of Science ®Google Scholar
• Song K, Eddington N. The impact of AT1002 on the delivery of ritonavir in the presence of bioadhesive polymer, carrageenan. Arch Pharm Res 2012;35(5):937-43
   PubMed Web of Science ®Google Scholar
• Uchida T, Kanazawa T, Takashima Y, Okada H. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002. Chem Pharm Bull 2011;59(2):196-201
   PubMed Web of Science ®Google Scholar
• Song K, Fasano A, Eddington ND. Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator. Eur J Pharm Biopharm 2008;69(1):231-7
   PubMed Web of Science ®Google Scholar
• Leffler DA, Kelly CP, Abdallah HZ, et al. A Randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 2012;107(10):1554-62
   PubMed Web of Science ®Google Scholar
• Kelly CP, Green PHR, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 2013;37(2):252-62
   PubMed Web of Science ®Google Scholar
• Cui K, Chen S-C, Houston ME, Quay SC. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds, United States Patent Application. US2006/0062758A1; 2006
   Google Scholar
• Johnson PH, Quay SC. Advances in nasal drug delivery through tight junction technology. Expert Opin Drug Deliv 2005;2(2):281-98
   PubMedGoogle Scholar
• Chen S, Eiting K, Cui K, et al. Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J Pharm Sci 2006;95(6):1364-71
   PubMed Web of Science ®Google Scholar
• Cui K, Chen Quay S-C, Fry KT. Tight junction modulating peptides for enhanced mucosal delivery of therapeutic compounds, United States Patent Application. US2007/0154449A1; 2007
   Google Scholar
• Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 2009;1788(4):892-910
   PubMed Web of Science ®Google Scholar
• A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00624767
   Google Scholar
• A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00537420?term=NCT00537420&rank=1
   Google Scholar
• Kirschner N, Bohner C, Rachow S, Brandner JM. Tight junctions: is there a role in dermatology? Arch Dermatol Res 2010;302(7):483-93
   PubMed Web of Science ®Google Scholar
• Furuse M, Hata M, Furuse K, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002;156(6):1099-111
   PubMed Web of Science ®Google Scholar
• Clayburgh DR, Rosen S, Witkowski ED, et al. A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability. J Biol Chem 2004;279(53):55506-13
   PubMed Web of Science ®Google Scholar
• Grindrod S, Suy S, Fallen S, et al. Effects of a fluorescent myosin light chain phosphatase inhibitor on prostate cancer cells. Front Oncol 2011;1:27
   PubMedGoogle Scholar
• Kato-Nakano M, Suzuki M, Kawamoto S, et al. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. Anticancer Res 2010;30(11):4555-62
   PubMed Web of Science ®Google Scholar
• Sanovich E, Bartus RT, Friden PM, et al. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995;705(1-2):125-35
   PubMed Web of Science ®Google Scholar
• Elliott PJ, Mackic JB, Graney WF, et al. RMP-7, a bradykinin agonist, increases permeability of blood-ocular barriers in the guinea pig. Invest Ophthalmol Vis Sci 1995;36(12):2542-7
   PubMed Web of Science ®Google Scholar
• Emerich DF, Snodgrass P, Pink M, et al. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7). Brain Res 1998;801(1-2):259-66
   PubMed Web of Science ®Google Scholar
• Barth RF, Yang W, Bartus RT, et al. Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog Cereport (Receptor-Mediated Permeabilizer-7). Neurosurgery 1999;44(2):351-9; discussion 359-60
   PubMed Web of Science ®Google Scholar
• Bartus RT, Elliott PJ, Dean RL, et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 1996;142(1):14-28
   PubMed Web of Science ®Google Scholar
• Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994;81(5):752-8
   PubMed Web of Science ®Google Scholar
• Emerich DF, Dean RL, Marsh J, et al. Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharm Res 2000;17(10):1212-19
   PubMed Web of Science ®Google Scholar
• Bartus RT, Snodgrass P, Dean RL, et al. Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies. Exp Neurol 2000;161(1):234-44
   PubMed Web of Science ®Google Scholar
• Bartus RT, Snodgrass P, Marsh J, et al. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. J Pharmacol Exp Ther 2000;293(3):903-11
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Black KL, Gobin YP, et al. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 1999;44(2):270-8; discussion 278-9
   PubMed Web of Science ®Google Scholar
• Warren K, Gervais A, Aikin A, et al. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother Pharmacol 2004;54(3):206-12
   PubMed Web of Science ®Google Scholar
• Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001;91(4):1487-500
   PubMed Web of Science ®Google Scholar
• Pellegrin S, Mellor H. Actin stress fibres. J Cell Sci 2007;120(20):3491-9
   PubMed Web of Science ®Google Scholar
• Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol 2003;4(3):225-36
   PubMed Web of Science ®Google Scholar
• Eto M, Ohmori T, Suzuki M, et al. A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. J Biochem 1995;118(6):1104-7
   PubMed Web of Science ®Google Scholar
• Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 2006;86(1):279-367
   PubMed Web of Science ®Google Scholar